BioCentury | Dec 1, 2020
Product Development

Nov. 30 Quick Takes: Grail piloting blood test in U.K.; plus Rhythm, Kadmon, venture rounds for Adrenomed, Xbiome, Transition

...By BioCentury Staff Grail piloting cancer blood test with NHS EnglandGrail Inc. announced a pilot program...
...ProopiomelanocortinROCK2 - Rho-associated coiled-coil containing protein kinase 2 BC Staff KD025, slx-2119, BN101 setmelanotide (RM-493, bim 22493, CAM-4072) Adrenomed Kadmon Grail Xbiome...
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

...Exact Sciences’ $2.2B acquisition of Thrive closely followed Illumina’s $8B takeout of Grail; could a Roche...
...the heels of the $8 billion takeout of Grail Inc. by Illumina Inc. (NASDAQ:ILMN), which had spu out Grail...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...Tuzman, Associate Editor As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s...
...opportunities for test developers.So far, no Chinese company has towered over the conversation the way Grail...
...detection of nasopharyngeal cancer, and was acquired by Grail in 2017 for an undisclosed amount. Grail...
BioCentury | Sep 30, 2020
Deals

Aptorum gains on blood-based pathogen surveillance tech licensed from A*STAR

...early cancer detection, most recently reflected in Grail Inc.’s $8 billion takeout by Illumina Inc. (NASDAQ:ILMN) (see “Grail...
BioCentury | Sep 22, 2020
Politics, Policy & Law

Azar’s memo & biotech’s deals: a BioCentury podcast

...financing environment for early-stage biotechs as well as Illumina’s move to acquire cancer detection company Grail.Washington...
...challenges of conducting investor pitches and due diligence virtually (see “Hexagon”; “Neogene”).The editors also discuss Grail...
...explores the deal in detail in Monday’s BioCentury (see “Grail Chooses Illumina Takeout Over IPO). BC Staff Illumina Grail...
BioCentury | Sep 22, 2020
Deals

Grail chooses Illumina takeout over IPO, promising more future returns for shareholders

...Illumina regains full control of Grail as the...
...public as planned, early cancer detection company Grail...
...investors, including Illumina, poured $1.9 billion into Grail...
BioCentury | Sep 16, 2020
Deals

A deal for Grail could be Illumina’s next shot at diversifying

...its bid to acquire PacBio, tools company Illumina is in talks to bring its spinout Grail...
...come cheap. The offer would likely come at a premium to the $6 billion valuation Grail...
...in the company (see “Grail’s Private Investors”; “Dozens of Investors Seek Liquidity as Grail Files for IPO”).Grail...
BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...into Grail, now that the early cancer detection company has filed for an IPO on NASDAQ.Grail...
...product. But given the amount of private funding the company has raised since early 2016, Grail...
...in IPO Plans”).Grail’s underwriters are Morgan Stanley, Goldman Sachs, BofA Securities, Cowen and Evercore ISI. Paul Bonanos Grail...
BioCentury | Jul 31, 2020
Finance

Data Bytes: Thrive megaround pours more cash into early cancer detection

...early cancer detection space is no stranger to eye-popping raises. The most notable case is Grail...
...detection program (see “Wave of Enthusiasm in Disease Detection” ). Karen Tkach Tuzman, Associate Editor Thrive Bioscience Inc. Grail...
BioCentury | Jul 30, 2020
Product Development

Thrive to leverage $257M series B to make case for broad access to CancerSEEK blood test

...will incorporate classification algorithms. At least three other companies are chasing liquid biopsy-based cancer detection: Grail...
Items per page:
1 - 10 of 195